Metformin for Idiopathic Pulmonary Fibrosis

(MAVRIC Trial)

This trial tests whether metformin can safely and effectively aid individuals with idiopathic pulmonary fibrosis (IPF), a lung disease that impairs breathing. It targets those at high risk of severe outcomes, identified by a specific blood test result. Participants will take either metformin or a placebo (a pill with no active drug) for up to two years. Those with a long history of IPF and frequent breathing problems might be suitable candidates. As a Phase 3 trial, this study represents the final step before FDA approval, providing participants an opportunity to contribute to potentially groundbreaking treatment advancements.

You may need to stop taking certain medications that interact with metformin, such as acetazolamide, cimetidine, and others listed in the trial's exclusion criteria. If you are on FDA-approved treatments for IPF, you must be on a stable dose for at least 8 weeks before joining the trial.

Research has shown that metformin, a common diabetes drug, has been tested for safety in people with idiopathic pulmonary fibrosis (IPF). Studies have found that patients generally tolerate metformin well. In one study, participants taking metformin had a lower risk of dying from any cause. However, some research suggests that metformin users might experience a worsening of their condition over time.

Unlike the standard treatments for idiopathic pulmonary fibrosis, which typically focus on slowing disease progression with drugs like pirfenidone and nintedanib, metformin offers a novel approach by potentially targeting underlying metabolic pathways. Researchers are excited about metformin because it has a different mechanism of action, primarily known for regulating glucose levels in diabetes, which may also influence lung tissue remodeling. This could open up new possibilities for managing the condition and provide additional benefits not addressed by current therapies.

Research suggests that metformin, a common diabetes medication, might benefit people with idiopathic pulmonary fibrosis (IPF), a lung disease. Some studies have shown that it could improve health outcomes for patients with type 2 diabetes. Metformin may reduce lung scarring and aid in lung cell healing. However, not all research agrees, and some studies have not found a significant benefit. In this trial, participants with a specific proteomic signature will receive either metformin or a placebo to further investigate its effects on IPF. It is important to remember that the effects of metformin on IPF are still under study, and more research is needed.²³⁵⁶⁷